Head to Head Comparison: Tevogen Bio (NASDAQ:TVGN) & Beam Therapeutics (NASDAQ:BEAM)

Tevogen Bio (NASDAQ:TVGN) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Institutional & Insider Ownership

99.7% of Beam Therapeutics shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Tevogen Bio has a beta of -1.05, indicating that its stock price is 205% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Tevogen Bio and Beam Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	0	0	1	0	3.00
Beam Therapeutics	0	4	6	0	2.60

Tevogen Bio currently has a consensus target price of $4.20, indicating a potential upside of 139.32%. Beam Therapeutics has a consensus target price of $45.80, indicating a potential upside of 89.81%. Given Tevogen Bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Beam Therapeutics.

Profitability

This table compares Tevogen Bio and Beam Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	-387.78%	434.75%
Beam Therapeutics	-40.56%	-16.22%	-10.65%

Earnings and Valuation

This table compares Tevogen Bio and Beam Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A
Beam Therapeutics	$377.71 million	5.27	-$132.53 million	($1.81)	-13.33

Tevogen Bio has higher earnings, but lower revenue than Beam Therapeutics.

Summary

Tevogen Bio beats Beam Therapeutics on 6 of the 11 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.